Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director · Chairman and CEO · 10% owner | July 09, 2019 | July 11, 2019 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · Chairman and CEO · 10% owner | January 12, 2023 | January 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promissory Note dated 9/14/17, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | Direct | 1 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. |
| Promissory Note dated 3/6/16, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | IndirectBy Hope International Hospice, Inc. | 1 |
Reported balance
After 2019-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown. |
Filing footnotes · ownership attribution and instrument terms
F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc.
F2: See footnote 1.
F3: Represents the outside date for completion of the proposed merger, unless extended by the parties.
F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction.
F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown.
Emmaus Life Sciences, Inc.
Report date January 12, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2028-01-11 | Direct | 0 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 7,500,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2020 Filed Mar 13, 2020 22:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $1.64 | $4,100.00 |
DisclosureSEC source: 0001209191-20-019028 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,477,643 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.70, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 21:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,750 | $1.82 | $6,825.00 |
DisclosureSEC source: 0001209191-20-017750 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,475,143 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.90, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 21:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 11,600 | $1.31 | $15,196.00 |
DisclosureSEC source: 0001209191-20-017750 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,471,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.45, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 27,500 | $1.45 | $39,875.00 |
DisclosureSEC source: 0001209191-20-017750 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,459,793 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.51, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 00:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,150 | $1.70 | $17,255.00 |
DisclosureSEC source: 0001209191-20-016772 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,432,293 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.70, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 00:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,850 | $1.64 | $7,954.00 |
DisclosureSEC source: 0001209191-20-016772 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,422,143 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.70, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 8,750 | $1.66 | $14,525.00 |
DisclosureSEC source: 0001209191-20-016772 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,417,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.80, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 21, 2020 Filed Feb 22, 2020 00:51 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 24,500 | $1.84 | $45,080.00 |
DisclosureSEC source: 0001209191-20-011812 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,408,543 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.68 to $1.91, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 20, 2020 Filed Feb 22, 2020 00:51 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 15,500 | $1.80 | $27,900.00 |
DisclosureSEC source: 0001209191-20-011812 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384,043 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.91, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 19, 2020 Filed Feb 22, 2020 00:51 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 8,000 | $1.70 | $13,600.00 |
DisclosureSEC source: 0001209191-20-011812 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,368,543 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.72, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 18, 2020 Filed Feb 18, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.72 | $6,880.00 |
DisclosureSEC source: 0001209191-20-010336 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,360,543 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.70 to $1.72, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,700 | $1.85 | $25,345.00 |
DisclosureSEC source: 0001209191-20-010336 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,356,543 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.87, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,050 | $1.80 | $9,090.00 |
DisclosureSEC source: 0001209191-20-010336 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,342,843 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.91, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 12, 2020 Filed Feb 12, 2020 23:49 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,400 | $1.86 | $8,184.00 |
DisclosureSEC source: 0001209191-20-008987 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,337,793 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.90, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 23:49 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 17,500 | $1.84 | $32,200.00 |
DisclosureSEC source: 0001209191-20-008987 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,333,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.89, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:49 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 9,200 | $1.71 | $15,732.00 |
DisclosureSEC source: 0001209191-20-008987 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,315,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.70 to $1.73, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), in footnote (3) and in footnote (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 17:29 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $1.46 | $7,300.00 |
DisclosureSEC source: 0001209191-20-007817 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,306,693 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.28 to $1.64, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 17:29 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,800 | $1.21 | $16,698.00 |
DisclosureSEC source: 0001209191-20-007817 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,301,693 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:15 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 16,500 | $2.98 | $49,170.00 |
DisclosureSEC source: 0001209191-19-054880 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,287,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.86 to $3.10, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 18:31 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $2.91 | $5,820.00 |
DisclosureSEC source: 0001209191-19-054693 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,271,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $2.95, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 18:31 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,500 | $2.57 | $8,995.00 |
DisclosureSEC source: 0001209191-19-054693 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,269,393 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.33 to $2.88, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 18:03 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,000 | $2.78 | $19,460.00 |
DisclosureSEC source: 0001209191-19-053674 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,265,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.80, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 16:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,500 | $2.72 | $17,680.00 |
DisclosureSEC source: 0001209191-19-053570 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,258,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 18:48 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 10,300 | $2.70 | $27,810.00 |
DisclosureSEC source: 0001209191-19-053259 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,252,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.76, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 18:48 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 8,800 | $2.45 | $21,560.00 |
DisclosureSEC source: 0001209191-19-053259 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,242,093 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.26 to $2.74, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 25, 2019 Filed Sep 26, 2019 18:51 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $2.29 | $11,450.00 |
DisclosureSEC source: 0001209191-19-050858 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,233,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.42, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 18:51 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $1.97 | $9,850.00 |
DisclosureSEC source: 0001209191-19-050858 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,228,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.82 to $2.10, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 21:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,827 | $4.26 | $12,043.02 |
DisclosureSEC source: 0001209191-19-048789 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 63,000 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.23 to $4.31, inclusive. Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 21:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 9,672 | $4.04 | $39,074.88 |
DisclosureSEC source: 0001209191-19-048789 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 60,173 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.92 to $4.10, inclusive. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 21:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 20,000 | $3.99 | $79,800.00 |
DisclosureSEC source: 0001209191-19-048789 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 50,501 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.96 to $4.04, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.30 | $330.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 25 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 30,501 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.28 | $328.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 24 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 30,401 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,630 | $3.27 | $5,330.10 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 23 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 30,301 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $3.26 | $1,956.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 22 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 28,671 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,100 | $3.25 | $10,075.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 21 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 28,071 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,100 | $3.24 | $3,564.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 20 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 24,971 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $3.23 | $646.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 19 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 23,871 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 470 | $3.22 | $1,513.40 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 18 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 23,671 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $3.21 | $1,605.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 17 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 23,201 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 400 | $3.20 | $1,280.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 16 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 22,701 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.19 | $319.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 15 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 22,301 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 900 | $3.18 | $2,862.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 14 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 22,201 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $3.18 | $6,350.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 13 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 21,301 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $3.17 | $7,925.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 12 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 19,301 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 800 | $3.17 | $2,532.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 11 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 16,801 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 300 | $3.16 | $948.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 10 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 16,001 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 300 | $3.16 | $946.50 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 9 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 15,701 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,300 | $3.15 | $4,095.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 8 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 15,401 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $3.15 | $1,887.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 7 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 14,101 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,400 | $3.14 | $4,389.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 6 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 13,501 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.